New model could lead to improved treatment for early stage Alzheimer's

February 28, 2013

Researchers at the University of Florida and The Johns Hopkins University have developed a line of genetically altered mice that model the earliest stages of Alzheimer's disease. This model may help scientists identify new therapies to provide relief to patients who are beginning to experience symptoms.

The researchers report their findings in the current issue of The .

"The development of this model could help scientists identify new ways to enhance brain function in patients in the early stages of the disease," said David Borchelt, UF professor of neuroscience in the Evelyn F. and William L. McKnight Brain Institute and director of the SantaFe HealthCare Alzheimer's Disease Research Center. "Such therapies could preserve longer and delay the appearance of more severe symptoms that leave patients unable to care for themselves."

In the early stages of Alzheimer's disease, people struggle with and fail to learn new games, rules or technologies because their decreases. The continues with memory loss and the decline of other brain functions.

The researchers worked with mice that had specially designed gene fragments derived from bacteria and from humans that allowed the investigators to control the production of a small peptide. The peptide, called amyloid beta peptide, is a short chain of . Accumulations of this particular peptide in the brain as lesions called plaques occur early in the progression of Alzheimer's disease and seem to trigger the early memory problems.

The team regulated the expression of the peptide using antibiotics—when the animals stopped taking the antibiotic, the peptide-producing gene turned on and caused the mice to develop the plaques found in Alzheimer's patients. After the mice had developed the Alzheimer pathology, the researchers turned the gene back off and observed that the mice showed persistent that resemble the early stages of the disease.

"This model may be useful to researchers to test drugs that could help with symptoms of early stage Alzheimer's disease," Borchelt said.

Explore further: A new gene thought to be the cause in early-onset forms of Alzheimer's disease

Related Stories

A new gene thought to be the cause in early-onset forms of Alzheimer's disease

April 4, 2012
A new gene that causes early-onset of Alzheimer's disease has been discovered by the research team of Dominique Campion at the Insert unit 1079 "Genetics of cancer and neuropsychiatric diseases" in Rouen. The research scientists ...

Tobacco-derived compound prevents memory loss in Alzheimer's disease mice

April 27, 2011
Cotinine, a compound derived from tobacco, reduced plaques associated with dementia and prevented memory loss in a mouse model of Alzheimer's disease, a study led by researchers at Bay Pines VA Healthcare System and the University ...

Sleep problems may be early sign of Alzheimer's

September 5, 2012
Sleep disruptions may be among the earliest indicators of Alzheimer's disease, scientists at Washington University School of Medicine in St. Louis report Sept. 5 in Science Translational Medicine.

Researchers find new target for Alzheimer's drug development

December 3, 2012
Researchers at the University of Minnesota's Center for Drug Design have developed a synthetic compound that, in a mouse model, successfully prevents the neurodegeneration associated with Alzheimer's disease.

Recommended for you

Researchers describe new biology of Alzheimer's disease

November 20, 2017
In a new study, researchers from Boston University School of Medicine (BUSM) describe a unique model for the biology of Alzheimer's disease (AD) which may lead to an entirely novel approach for treating the disease. The findings ...

Study shows video games could cut dementia risk in seniors

November 16, 2017
Could playing video games help keep the brain agile as we age?

New player in Alzheimer's disease pathogenesis identified

November 14, 2017
Scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have shown that a protein called membralin is critical for keeping Alzheimer's disease pathology in check. The study, published in Nature Communications, ...

Biomarker may predict early Alzheimer's disease

November 10, 2017
Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified a peptide that could lead to the early detection of Alzheimer's disease (AD). The discovery, published in Nature Communications, may ...

Smell test challenge suggests clinical benefit for some before development of Alzheimer's

November 10, 2017
Researchers at Columbia University Medical Center (CUMC) and the New York State Psychiatric Institute (NYSPI) may have discovered a way to use a patient's sense of smell to treat Alzheimer's disease before it ever develops. ...

How SORLA protects against Alzheimer's disease

November 7, 2017
Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified a new protective function for a brain protein genetically linked to Alzheimer's. The findings, published in the Journal of Experimental ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.